| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H29F2NO |
| Molar mass | 385.499 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JHW-007 is a cocaine analogue and a high affinity atypical dopamine reuptake inhibitor that is being researched for the treatment of cocaine addiction. JHW-007 has been found to blunt the psychostimulant effects of cocaine and reduce self-administration in rodents. JHW-007 exposure has been shown to block the conditioned place preference effects of cocaine. JHW-007 may directly antagonize the autoregulatory dopamine D2 receptor, a hypothesis that was developed following the observation of JHW-007's ability to inhibit D2 receptor-mediated currents in the midbrain.
In contrast to cocaine and other cocaine-like dopamine reuptake inhibitors, JHW-007 binds to the dopamine transporter (DAT) in an occluded (closed) conformation, similar to (R)-modafinil. This type of receptor binding to the DAT has been observed to result in a gradual and sustained increase in extracellular dopamine in the nucleus accumbens. Peak levels of extracellular dopamine are also markedly reduced. Both modafinil and JHW-007 have been investigated for the treatment of cocaine addiction.
| Adamantanes | |
|---|---|
| Adenosine antagonists | |
| Alkylamines | |
| Ampakines | |
| Arylcyclohexylamines | |
| Benzazepines | |
| Cathinones |
|
| Cholinergics |
|
| Convulsants | |
| Eugeroics | |
| Oxazolines | |
| Phenethylamines |
|
| Phenylmorpholines | |
| Piperazines | |
| Piperidines |
|
| Phenethylpyrrolidines | |
| Racetams | |
| Psychedelics | |
| Tropanes |
|
| Tryptamines | |
| Others |
|